The Business Times
SUBSCRIBERS

Valeant investors doubting drugmaker's chief can regain grip

The company is in worse shape after Michael Pearson returned from a two-month medical leave for pneumonia

google-preferred-sourceAdd BT as a preferred source
Published Wed, Mar 16, 2016 · 09:50 PM

    Boston

    MICHAEL Pearson and his company, Valeant Pharmaceuticals International Inc, were supposed to calm Wall Street doubters on Tuesday. Instead: chaos.

    What began before dawn with disappointing financial news quickly snowballed into the worst day in the drug company's history, leaving investors wondering if Mr Pearson, its controversial chief, can regain his grip.

    Share with us your feedback on BT's products and services

    Feedback
    Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
    Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
    View More